Published Date: 08 Mar 2023
The White House said Friday it was "dangerous and unacceptable" for elected officials to target women's access to federally-approved abortion pills.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia
COPD in 2025: Year in Review
FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector
Nephrology in 2025: Year in Review
1.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
2.
Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions
3.
Is global cancer care losing its human touch?
4.
After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.
5.
FDA Approves New Bladder Cancer First-Line Standard of Care.
1.
Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma
2.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
3.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
4.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
5.
Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation